Extensive Left Ventricular Remodeling Does Not Allow Viable Myocardium to Improve in Left Ventricular Ejection Fraction After Revascularization and is Associated with Worse Long-term Prognosis
Overview
Authors
Affiliations
Background: Extensive left ventricular (LV) remodeling may not allow functional recovery after revascularization, despite the presence of viable myocardium.
Methods And Results: Seventy-nine consecutive patients with ischemic cardiomyopathy (left ventricle ejection fraction [LVEF] 29+/-7%) underwent surgical revascularization. Before revascularization, viability was assessed by metabolic imaging with F18-fluorodeoxyglucose and SPECT. LV volumes and LVEF were assessed by resting echocardiography. LVEF was re-assessed by echocardiography 8 to 12 months after revascularization. Three-year clinical follow-up (events: cardiac death, infarction, and hospitalization for heart failure) was also obtained. Forty-nine patients had substantial viability; 5 died before re-assessment of LVEF. Of the remaining 44 patients, 24 improved > or =5% in LVEF after revascularization, whereas 20 did not improve in LVEF. LV end-systolic volume was the only parameter that was significantly different between the groups (109+/-46 mL for the improvers versus 141+/-31 mL for the nonimprovers; P<0.05). The change in LVEF after revascularization was linearly related to the baseline LV end-systolic volume, with a higher LV end-systolic volume associated with a low likelihood of improvement in LVEF after revascularization. During the 3-year follow-up, the highest event-rate (67%) was observed in patients without viable myocardium with a large LV size, whereas the lowest event rate (5%) was observed in patients with viable myocardium and a small LV size. Intermediate event rates were observed in patients with viable myocardium and a large LV size (38%), and in patients without viable myocardium and a small LV size (24%).
Conclusions: Extensive LV remodeling prohibits improvement in LVEF after revascularization and affects long-term prognosis negatively, despite the presence of viability.
Dong Y, Xu Z, Dai X, Chen L, Lin Z Rev Cardiovasc Med. 2024; 25(9):317.
PMID: 39355578 PMC: 11440416. DOI: 10.31083/j.rcm2509317.
Arjomandi Rad A, Tserioti E, Magouliotis D, Vardanyan R, Samiotis I, Skoularigis J Clin Cardiol. 2024; 47(7):e24307.
PMID: 38953367 PMC: 11217808. DOI: 10.1002/clc.24307.
Cao J, Yu M, Xiao Y, Dong R, Wang J Front Cardiovasc Med. 2024; 11:1398700.
PMID: 38895539 PMC: 11183324. DOI: 10.3389/fcvm.2024.1398700.
Shrestha U, Chae H, Fang Q, Lee R, Packiasamy J, Huynh L Res Sq. 2024; .
PMID: 38746162 PMC: 11092840. DOI: 10.21203/rs.3.rs-4244476/v1.
Varma P, Radhakrishnan R, Gopal K, Krishna N, Jose R Indian J Thorac Cardiovasc Surg. 2024; 40(3):341-352.
PMID: 38681722 PMC: 11045715. DOI: 10.1007/s12055-023-01671-9.